In contrast, MAO-B inhibitors may improve both depression and motivation symptoms, though the latter effect may be dependent on the severity of striatal dopaminergic neurodegeneration, potentially as a consequence of their mechanism of action depending on pre-synaptic dopaminergic neuron integrity. Here, MAOB is linked to depressive symptom measurement.